UK markets closed

Actinium Pharmaceuticals, Inc. (ATNM)

NYSE American - Nasdaq Real-time price. Currency in USD
Add to watchlist
8.43+0.65 (+8.35%)
As of 11:58AM EDT. Market open.
Currency in USD

Valuation measures4

Market cap (intra-day) 231.72M
Enterprise value 149.64M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.61k
Price/book (mrq)5.28
Enterprise value/revenue 1.85k
Enterprise value/EBITDA -3.05

Trading information

Stock price history

Beta (5Y monthly) 0.08
52-week change 3-12.29%
S&P500 52-week change 323.57%
52-week high 39.86
52-week low 34.00
50-day moving average 37.85
200-day moving average 36.24

Share statistics

Avg vol (3-month) 3372.44k
Avg vol (10-day) 3258.97k
Shares outstanding 529.78M
Implied shares outstanding 629.78M
Float 829M
% held by insiders 12.13%
% held by institutions 124.12%
Shares short (15 Apr 2024) 41.98M
Short ratio (15 Apr 2024) 43.04
Short % of float (15 Apr 2024) 46.73%
Short % of shares outstanding (15 Apr 2024) 46.73%
Shares short (prior month 15 Mar 2024) 41.82M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 311 Aug 2020
Ex-dividend date 4N/A
Last split factor 21:30
Last split date 311 Aug 2020

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-61,645.68%

Management effectiveness

Return on assets (ttm)-32.78%
Return on equity (ttm)-91.92%

Income statement

Revenue (ttm)81k
Revenue per share (ttm)0.00
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -49.69M
Net income avi to common (ttm)-46.45M
Diluted EPS (ttm)-1.71
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)84.06M
Total cash per share (mrq)2.82
Total debt (mrq)1.98M
Total debt/equity (mrq)4.52%
Current ratio (mrq)10.59
Book value per share (mrq)1.49

Cash flow statement

Operating cash flow (ttm)-39.63M
Levered free cash flow (ttm)-23.38M